arrow
S

Soo Heon Kwak

Seoul National University Hospital
H指数:51
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial

Teneligliptin作为添加疗法在经Empagliflozin和Metformin治疗的患者中的疗效与安全性:一项为期24周、随机、双盲、安慰剂对照的III期临床试验

2026-11-140
OA
β‐Cell Recovery Patterns With Initial Combination Versus Stepwise Therapy in Newly Diagnosed Type 2 Diabetes: TRIPLE ‐ AXEL Post Hoc Analysis

新诊断2型糖尿病中初始联合治疗与逐步治疗后的β细胞恢复模式:<scp>TRIPLE</scp>‐<scp>AXEL</scp>事后分析

2026-11-030
PRE
Multi-ancestry, trans-generational GWAS meta-analysis of gestational diabetes and glycaemic traits during pregnancy reveals limited evidence of pregnancy-specific genetic effects

多族裔、跨代的全基因组关联研究荟萃分析:妊娠糖尿病及孕期糖代谢性状揭示有限的妊娠特异性遗传效应

2026-06-010
OAAI
Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover Trial

与胰高血糖素样肽-1反应受损相关的2型糖尿病中德谷胰岛素/门冬胰岛素与基础胰岛素相比的降糖益处:一项随机交叉试验

2026-05-010
PRE
Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial

西格列汀和恩格列净固定剂量组合作为二甲双胍的加用药物在韩国2型糖尿病患者中的疗效与安全性:一项随机、双盲、多中心、安慰剂对照、III期试验

2026-03-260
OAAI
Diabetic foot ulcer-related amputation is associated with twofold increased risk of cardiovascular disease: A Korean National Health Information Database Study

糖尿病足溃疡相关截肢与心血管疾病风险增加两倍相关:一项基于韩国国民健康信息数据库的研究

2026-03-010
OAAI
Real-time continuous glucose monitoring improves postoperative glucose control in people with type 2 diabetes mellitus undergoing coronary artery bypass grafting: A randomized clinical trial

实时连续血糖监测改善2型糖尿病患者冠状动脉旁路移植术后血糖控制: 一项随机临床试验

2025-01-070
PRE